Product Profiles: Bipolar Disorders - Me-too drug development strategy unsustainable

Oct. 20, 2011 - PRLog -- Introduction
Despite increasing generic competition, drug developers remain interested in bipolar disorders. The US Food and Drug Administration (FDA) approved Risperdal Consta (risperidone long-acting injection; Johnson & Johnson) and Saphris (asenapine; Merck & Co./Lundbeck) for bipolar disorders in May 2009 and August 2009 respectively.

Browse All:  http://www.reportsnreports.com/reports/134882-product-profiles-bipolar-disorders-me-too-drug-development-str.html

Features and benefits
•   Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating bipolar disorder product profile.
•   Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
•   Assessment of the strengths, weaknesses, opportunities, and threats for key marketed and pipeline therapies.
•   Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
•   Determine to what extent future therapies satisfy the main clinical unmet needs in the treatment of bipolar disorders.

Highlights

The patent expiries of several atypical antipsychotics brands are imminent and competition within the bipolar disorders market is set to intensify. Prospective market entrants must demonstrate improved efficacy in bipolar depression and maintenance treatment in order to successfully penetrate this highly genericized market.

As the current atypical antipsychotics have been in the market for almost a decade, Saphris (asenapine; Merck & Co./Lundbeck) will struggle to compete with olanzapine and quetiapine on account of its late market entry and me too mechanism of action.

Psychostimulant therapies have the potential to expand the range of treatment options for bipolar depression, thereby addressing a key unmet need. However, it will be necessary for manufactures of psychostimulants pursuing the bipolar depression indication to assuage physicians’ concerns that such drugs may trigger a manic episode.

About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

# # #

ReportsnReports houses a comprehensive online library of more than 50,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites.